Business Context and Reporting Period
This Form 8-K was filed by Enochian Biosciences Inc. (trading symbol: ENOB) on July 8, 2020. The filing reports the entry into a Material Definitive Agreement with Lincoln Park Capital Fund, LLC ("LPC"). The company is a Delaware corporation focused on biotechnology, with principal executive offices in Los Angeles, CA.
Key Financial Metrics and Transaction Details
This filing does not contain historical financial statements, revenue, profit, or cash flow data. The primary financial metric disclosed is the potential capital raise under a new purchase agreement:
- Total Commitment: Up to $20,000,000 in common stock sales over a 36-month period.
- Regular Purchase Limit: Up to 50,000 shares per business day (increasing to 125,000 shares under certain market conditions), with a maximum daily obligation of $1,000,000.
- Exchange Cap: Sales are limited to 9,299,480 shares (19.99% of outstanding shares) unless shareholder approval is obtained or specific pricing thresholds are met.
- Beneficial Ownership Limit: LPC cannot be directed to purchase shares if it would result in beneficial ownership exceeding 9.99% of total outstanding shares.
- Issuance for Agreement: The company issued 139,567 shares of common stock as consideration for entering the agreement.
Material Changes and Transaction Structure
The material change reported is the establishment of an "At-the-Market" style sales facility with LPC. Key structural elements include:
- Pricing: Purchase prices are based on prevailing market prices at the time of sale; there are no fixed price limits.
- Flexibility: The company may terminate the agreement at any time without cost.
- Restrictions: The company is prohibited from entering into "Variable Rate Transactions" (e.g., floating conversion rates) during the 36-month term, though other capital raising methods remain available.
- Short Selling: LPC has covenanted not to engage in direct or indirect short selling or hedging of the company's stock.
Guidance, Outlook, and Risks
Use of Proceeds: The company intends to use proceeds for general corporate purposes, including working capital, capital expenditures, and funding preclinical and potentially future clinical development of pipeline candidates.
Risks and Forward-Looking Statements: The filing includes standard forward-looking statements regarding the intended use of proceeds and future development. Actual results may differ materially due to uncertainties inherent in biotechnology development and capital markets. The filing explicitly states that the company undertakes no obligation to update these statements.
Investor Verification Checklist
- Verify the current number of outstanding shares to calculate the precise percentage dilution if the full $20,000,000 is utilized.
- Review the full text of the Purchase Agreement (Exhibit 10.1) for specific definitions of "Regular Purchases" and "Accelerated Purchases."
- Monitor the company's subsequent filings to track the actual volume of shares sold under this agreement and the average price realized.
- Confirm whether the company has initiated any other capital raising activities that might interact with the "Variable Rate Transaction" restrictions.
- Check for any shareholder approval filings if the company intends to exceed the 19.99% Exchange Cap.